Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

451 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL.
Dumas PY, Naudin C, Martin-Lannerée S, Izac B, Casetti L, Mansier O, Rousseau B, Artus A, Dufossée M, Giese A, Dubus P, Pigneux A, Praloran V, Bidet A, Villacreces A, Guitart A, Milpied N, Kosmider O, Vigon I, Desplat V, Dusanter-Fourt I, Pasquet JM. Dumas PY, et al. Among authors: milpied n. Haematologica. 2019 Oct;104(10):2017-2027. doi: 10.3324/haematol.2018.205385. Epub 2019 Mar 28. Haematologica. 2019. PMID: 30923103 Free PMC article. Clinical Trial.
Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R, Guillaume T, Avet-Loiseau H, Dmytruk N, Girault S, Milpied N, Ifrah N, Mohty M, Harousseau JL. Chevallier P, et al. Among authors: milpied n. J Clin Oncol. 2008 Nov 10;26(32):5192-7. doi: 10.1200/JCO.2007.15.9764. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854573 Clinical Trial.
Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD.
Labouré G, Dulucq S, Labopin M, Tabrizi R, Guérin E, Pigneux A, Lafarge X, Leguay T, Bouabdallah K, Dilhuydy MS, Duclos C, Lascaux A, Marit G, Mahon FX, Boiron JM, Milpied N, Vigouroux S. Labouré G, et al. Among authors: milpied n. Biol Blood Marrow Transplant. 2012 Dec;18(12):1845-50. doi: 10.1016/j.bbmt.2012.06.012. Epub 2012 Jul 2. Biol Blood Marrow Transplant. 2012. PMID: 22766221 Free article.
Sequential treatment for allogeneic hematopoietic stem cell transplantation in Fanconi anemia with acute myeloid leukemia.
Talbot A, Peffault de Latour R, Raffoux E, Buchbinder N, Vigouroux S, Milpied N, Leblanc T, Soulier J, Michallet M, Socié G. Talbot A, et al. Among authors: milpied n. Haematologica. 2014 Oct;99(10):e199-200. doi: 10.3324/haematol.2013.098954. Epub 2014 Aug 1. Haematologica. 2014. PMID: 25085358 Free PMC article. No abstract available.
Transient grades 3 to 4 acute hepatitis is a common complication of rabbit antithymocyte globulin (thymoglobulin) administered before allogeneic stem cell transplantation.
Médiavilla C, Vigouroux S, Tabrizi R, Pigneux A, Duclos C, Mohr C, Robles M, Milpied N. Médiavilla C, et al. Among authors: milpied n. Biol Blood Marrow Transplant. 2015 Apr;21(4):661-5. doi: 10.1016/j.bbmt.2014.12.014. Epub 2014 Dec 20. Biol Blood Marrow Transplant. 2015. PMID: 25536216 Free article.
Risk Factors for Steroid-Refractory Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation from Matched Related or Unrelated Donors.
Calmettes C, Vigouroux S, Labopin M, Tabrizi R, Turlure P, Lafarge X, Marit G, Pigneux A, Leguay T, Bouabdallah K, Dilhuydy MS, Duclos C, Mohr C, Lascaux A, Dumas PY, Dimicoli-Salazar S, Saint-Lézer A, Milpied N. Calmettes C, et al. Among authors: milpied n. Biol Blood Marrow Transplant. 2015 May;21(5):860-5. doi: 10.1016/j.bbmt.2015.01.016. Epub 2015 Jan 21. Biol Blood Marrow Transplant. 2015. PMID: 25617807 Free article.
451 results